Dosage ; Prophylaxis of angina: 1 tablet in the morning
increased to 2 tablets when required
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Imdur | AstraZeneca | Radiance Pharmaceuticals Limited | 60mg | 30 | Tablet | per tablet | KES 2,129.00 |
| Isosorbide Mononitrate | Arrow Generics | Metro Pharmaceuticals Ltd. | 10mg | 56 | Tablet | per tablet | KES 350.00 |
| Isosorbide Mononitrate | Arrow Generics | Metro Pharmaceuticals Ltd. | 20mg | 56 | Tablet | per tablet | KES 350.00 |
| Isosorbide Mononitrate | Arrow Generics | Metro Pharmaceuticals Ltd. | 20mg | 30 | Tablet | per tablet | KES 350.00 |
| Monis | Maple Pharmaceuticals Pvt. Ltd | Njimia Pharmaceuticals Ltd. | 20mg | 20 | Tablet | per tablet | KES 500 |
| Monotrate OD | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 50mg | 50 | Tablet | per tablet | KES 2,400 |
| Monotrate | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 20mg | 100 | Tablet | per tablet | KES 2,450.00 |
| Isosorbide Mononitrate | |
|---|---|
| Drug Indication | Angina, Left ventricular failure. |
| Contra-Indications | allergy to nitrates, closed angle glaucoma, head trauma, hypotension, severe anaemia, allergy to adhesives. Cardia temponade, pregnancy |
| Side Effects | Throbbing headache, mental disturbances, insomnia, nausea and vomiting, flushing, postural hypotension, tachycardia, impotence, dysuria, involuntary passing of urine and stool |
| Dosage | Prophylaxis of angina: 1 tablet in the morning increased to 2 tablets when required. |
| Pregnancy Category | Category B2 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |
| Drug Sub-Category | Nitrates |